Zymeworks Inc (NASDAQ:ZYME) has earned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $16.00.
Several equities research analysts have issued reports on the company. Cormark reaffirmed a “buy” rating on shares of Zymeworks in a report on Saturday, September 30th. Zacks Investment Research raised Zymeworks from a “sell” rating to a “hold” rating in a report on Saturday, September 9th. Scotiabank downgraded Zymeworks from an “overweight” rating to an “underweight” rating in a report on Thursday, September 7th. Finally, Barclays PLC reaffirmed an “underweight” rating and set a $8.00 price target on shares of Zymeworks in a report on Thursday, September 7th.
Zymeworks (NASDAQ:ZYME) traded up 4.1491% during trading on Monday, reaching $9.0818. 18,574 shares of the company traded hands. The company’s 50-day moving average is $7.92 and its 200 day moving average is $9.06. The company’s market cap is $230.12 million. Zymeworks has a 12 month low of $6.25 and a 12 month high of $14.25.
Several institutional investors and hedge funds have recently bought and sold shares of the company. OxFORD Asset Management LLP acquired a new stake in shares of Zymeworks during the second quarter worth $154,000. Franklin Resources Inc. acquired a new stake in shares of Zymeworks during the second quarter worth $6,878,000. Sentry Investments Corp. acquired a new stake in shares of Zymeworks during the second quarter worth $206,000. Finally, Barometer Capital Management Inc. acquired a new stake in shares of Zymeworks during the second quarter worth $484,000.
TRADEMARK VIOLATION WARNING: “Zymeworks Inc (ZYME) Receives $16.00 Consensus Price Target from Brokerages” was originally posted by Equities Focus and is the sole property of of Equities Focus. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.equitiesfocus.com/2017/10/05/zymeworks-inc-zyme-receives-16-00-consensus-price-target-from-brokerages.html.
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.